🔥🐔 BizChicken 🐔🔥
Companies Similar to Solid Biosciences Inc.
Sign Up Today!
Sign up for BizChicken and discover more about the corporations around you.
Mustang Bio, Inc.
Gene and CAR T Cell Therapies
Mustang Bio, Inc. is a biopharmaceutical company specializing in cell and gene therapies for hematologic cancers, solid tumors, and rare genetic diseases. It focuses on developing gene therapy programs and CAR T cell therapies, including treatments for X-linked severe combined immunodeficiency and various types of cancer.
About | Leadership | Directors | News | Contact | About | About | Careers | About | About | Careers | About | About
Symbol: MBIO
Recent Price: $0.19
Industry: Biotechnology
CEO: Dr. Manuel Litchman M.D.
Sector: Healthcare
Employees: 80
Address: 377 Plantation Street, Worcester, MA 01605
Phone: 781 652 4500
Leadership
- Manuel Litchman, M.D., President, Chief Executive Officer and Director
- Greg Furrow, M.S., FRQA, Chief Quality Officer
- James Murphy, B.A., Ad interim Chief Financial Officer
- Michael S. Weiss, Chairman of the Board of Directors
- Lindsay A. Rosenwald, M.D., Director
- Adam J. Chill, Director
- Neil Herskowitz, Director
- Michael J. Zelefsky, M.D., Director
- Mustang Bio, Inc., Company
Last updated: 2024-12-31
Sangamo Therapeutics, Inc.
ZFP Technology Platform
Sangamo Therapeutics, Inc. is a clinical-stage biotechnology company that develops genomic medicines using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation with a focus on transforming patients' lives.
Contact | About | About | Leadership | Leadership | About | About | About | About | About | About | About | About | About | About | Careers | Vision/Values | DEI | Benefits | About | About | About | About | About | About | About | News | Events | Vision/Values | DEI | Benefits | Careers | Careers | About | About
Symbol: SGMO
Recent Price: $2.34
Industry: Biotechnology
CEO: Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D.
Sector: Healthcare
Employees: 405
Address: 501 Canal Blvd, Brisbane California, CALIFORNIA 94005
Phone: 510 970 6000
Leadership
- Sandy Macrae, M.B., Ch.B., Ph.D.,
- Gregory Davis, Ph.D., Head of Research and Technology
- Nathalie Dubois-Stringfellow, Ph.D., Chief Development Officer
- Prathyusha Duraibabu, Chief Financial Officer
- Phillip Ramsey, Head of Technical Operations
- Stephanie J. Seiler, CLP, Head of Business Development & Alliance Management
- Louise Wilkie, Global Corporate Communications and Investor Relations
- Scott Willoughby, General Counsel and Corporate Secretary
- H. Stewart Parker, Chair of the Board
- Courtney Beers, Ph.D.,
- Robert Carey,
- Kenneth Hillan, M.B. Ch.B.,
- Margaret (Peg) A. Horn, J.D.,
- John Markels, Ph.D.,
- James R. Meyers,
- Karen Smith, M.D., Ph.D., M.B.A., LLM,
Last updated: 2024-12-31
Sarepta Therapeutics, Inc.
EXONDYS 51, VYONDYS 53, AMONDYS 45, SRP-5051, SRP-9001, SRP-9003
Sarepta Therapeutics, Inc. is a biopharmaceutical company focused on developing RNA-targeted therapeutics and gene therapies for rare diseases, including treatments for Duchenne muscular dystrophy.
Contact | About | Leadership | About | About | About | Locations | About | About | About | About
Symbol: SRPT
Recent Price: $121.19
Industry: Biotechnology
CEO: Mr. Douglas S. Ingram Esq.
Sector: Healthcare
Employees: 1314
Address: 215 First Street, Cambridge, MA 02142
Phone: 617 274 4000
Leadership
- Douglas S. Ingram, President and Chief Executive Officer
- Bilal Arif, Executive Vice President, Chief Technical Operations Officer
- Diane Berry, PhD, Executive Vice President, Chief Global Policy & Advocacy Officer
- Ryan E. Brown, JD, Executive Vice President, Chief General Counsel
- Ian M. Estepan, Executive Vice President, Chief Financial Officer
- Dallan Murray, Executive Vice President, Chief Customer Officer
- Alison Nasisi, Executive Vice President, Chief People Officer
- Louise R. Rodino-Klapac, PhD, Executive Vice President, Head of R&D, Chief Scientific Officer
- Will Tilton, Senior Vice President, Head of Strategy, Chief of Staff
- M. Kathleen Behrens, PhD, Chairwoman
- Richard J. Barry,
- Kathryn Boor, PhD,
- Michael Chambers,
- Deirdre Connelly,
- Stephen L. Mayo, PhD,
- Claude Nicaise, MD,
- Hans Wigzell, MD, PhD,
- John C. Martin, PhD (In Memoriam),
- Annemieke Aartsma-Rus, PhD,
- Carsten Bönnemann, MD,
- Joy Cavagnaro, PhD, DABT, Fellow ATS,
- Kay Davies, PhD, DBE FMedSci FRS,
- Steven Gray, PhD,
- Angela J. Russell, DPhil,
Last updated: 2024-12-31
Adicet Bio, Inc.
ADI-001
Adicet Bio, Inc. is a biotechnology company focused on discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Their lead product ADI-001 is in Phase I clinical study for non-Hodgkin's lymphoma, with additional products in development for solid tumors.
Symbol: ACET
Recent Price: $0.90
Industry: Biotechnology
CEO: Mr. Chen Schor BA, CPA, M.B.A.
Sector: Healthcare
Employees: 143
Address: 200 Clarendon Street, Boston, MA 02116
Phone: 650 503 9095
Last updated: 2024-12-31
Beam Therapeutics Inc.
precision genetic medicines
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States, with a focus on conditions such as sickle cell disease, beta thalassemia, and Glycogen Storage Disease Type Ia.
About | Contact | Careers | Careers | Careers | Careers | Jobs | Careers | About | About | About | Careers | About | Jobs | Careers
Symbol: BEAM
Recent Price: $25.28
Industry: Biotechnology
CEO: Mr. John M. Evans M.B.A.
Sector: Healthcare
Employees: 472
Address: 238 Main Street, Cambridge, MA 02142
Phone: 857 327 8775
Last updated: 2024-12-31
Cabaletta Bio, Inc.
DSG3-CAART
Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on developing engineered T cell therapies for B cell-mediated autoimmune diseases. Its leading product, DSG3-CAART, is in Phase I trials for treating mucosal pemphigus vulgaris.
Symbol: CABA
Recent Price: $2.24
Industry: Biotechnology
CEO: Dr. Steven A. Nichtberger M.D.
Sector: Healthcare
Employees: 136
Address: 2929 Arch Street, Philadelphia, PA 19104
Phone: 267 759 3100
Leadership
- Steven Nichtberger, M.D., President, Chief Executive Officer, and Co-Founder
- Samik Basu, M.D., Chief Scientific Officer
- Gwendolyn Binder, Ph.D., President, Science & Technology
- David J. Chang, M.D., M.P.H, FACR, Chief Medical Officer
- Arun Das, M.D., Chief Business Officer
- Michael Gerard, General Counsel
- Heather Harte-Hall, Chief Compliance Officer
- Anup Marda, Chief Financial Officer
- Martha O’Connor, Chief Human Resources Officer
- Sarah Yuan, Ph.D., Chief Technology Officer
- Catherine Bollard, M.D., Independent Director, George Washington University
- Scott Brun, M.D., Independent Director, formerly at AbbVie
- Richard Henriques, M.B.A., Independent Director, former CFO of Gates Foundation, former Controller at Merck
- Mark Simon, M.B.A., Independent Director, Torreya Partners
- Shawn Tomasello, M.B.A., Independent Director, former CCO of Kite Pharma, Inc.
Last updated: 2024-12-31
Celcuity Inc.
CELsignia diagnostic platform
Celcuity Inc., a biotechnology company, develops targeted therapies for cancer patients in the US, including the CELsignia diagnostic platform and Gedatolisib drug candidate.
Symbol: CELC
Recent Price: $13.13
Industry: Biotechnology
CEO: Mr. Brian F. Sullivan
Sector: Healthcare
Employees: 55
Address: 16305–36th Avenue North, Minneapolis, MN 55446
Phone: 763 392 0767
Leadership
- Brian Sullivan, CEO and Co-founder
- Lance Laing, PhD, Chief Science Officer and Co-founder
- Vicky Hahne, CFO
- Igor Gorbatchevsky, MD, Chief Medical Officer
- Eldon Mayer, Chief Commercial Officer
- Brent Eilefson, General Counsel
- Bernhard Lampert, PhD, VP of Pharmaceutical Development
- Nadene Zack, VP Clinical Operations
- Sunni Miller, VP of Regulatory Affairs
- David Bridge, VP of Quality Assurance and Process Development
- William Strickland, PharmD, VP of Medical Affairs
- Fred Kerwood, VP of Program Management
- Charlotte Moser, MD, PhD, SVP of Clinical Development
- John R. MacDonald, PhD, SVP of R&D
- Lance Laing, PhD, Chief Science Officer and Co-Founder
- Richard Buller, MD, PhD, Director
- David F. Dalvey, Director
- Leo Furcht, MD, Director
- Polly Murphy, DVM, PhD, Director
- Richard J. Nigon, Director
Last updated: 2024-12-31
Cogent Biosciences, Inc.
CGT9486
Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies for genetically defined diseases, with lead product candidate CGT9486 targeting mutations driving systemic mastocytosis and advanced gastrointestinal stromal tumors.
Symbol: COGT
Recent Price: $7.67
Industry: Biotechnology
CEO: Mr. Andrew R. Robbins M.B.A.
Sector: Healthcare
Employees: 164
Address: 200 Cambridge Park Drive, Cambridge, MA 02140
Phone: 617 945 5576
Last updated: 2024-12-31
Design Therapeutics, Inc.
Gene TAC
Design Therapeutics, Inc. is a preclinical-stage biopharmaceutical company developing therapies for genetic diseases caused by nucleotide repeat expansions. Their portfolio includes products targeting Friedreich Ataxia and Myotonic Dystrophy Type-1, as well as Gene TAC candidates for other similar diseases.
About | Contact | Careers | About | About | About | About | About | News | About | Careers | About
Symbol: DSGN
Recent Price: $6.17
Industry: Biotechnology
CEO: Mr. Pratik Shah Ph.D.
Sector: Healthcare
Employees: 57
Address: 6005 Hidden Valley Road, Carlsbad, CA 92011
Phone: 858 293 4900
Last updated: 2024-12-31
4D Molecular Therapeutics, Inc.
4D-125, 4D-110, 4D-310, 4D-150, 4D-710
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company developing product candidates using adeno-associated virus vectors, focusing on ophthalmology, cardiology, and pulmonology.
About | About | Contact | News | News | News | Careers | Careers | About | DEI | Careers | Leadership | Careers | Careers
Symbol: FDMT
Recent Price: $5.30
Industry: Biotechnology
CEO: Dr. David H. Kirn M.D.
Sector: Healthcare
Employees: 201
Address: 5858 Horton Street, EmeryVille, CA 94608
Phone: 510 505 2680
Last updated: 2024-12-31
Generation Bio Co.
genetic medicines
Generation Bio Co. is a genetic medicines company developing therapies for rare and prevalent diseases, with a focus on the liver, retina, skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and is headquartered in Cambridge, Massachusetts.
Symbol: GBIO
Recent Price: $1.06
Industry: Biotechnology
CEO: Dr. Cameron Geoffrey McDonough M.D.
Sector: Healthcare
Employees: 174
Address: 301 Binney Street, Cambridge, MA 02142
Phone: 617 655 7500
Last updated: 2024-12-31
PepGen Inc.
PGN-EDO51
Pep Gen Inc. is a clinical-stage biotechnology company developing oligonucleotide therapeutics for neuromuscular and neurologic diseases. Its lead product, PGN-EDO51, is in Phase I trials for Duchenne muscular dystrophy.
Symbol: PEPG
Recent Price: $3.83
Industry: Biotechnology
CEO: Dr. James G. McArthur Ph.D.
Sector: Healthcare
Employees: 72
Address: 245 Main Street, Cambridge, MA 02142
Phone: 781-797-0979
Last updated: 2024-12-31
Regulus Therapeutics Inc.
RG-012 and RGLS8429
Regulus Therapeutics Inc., based in San Diego, focuses on discovering and developing drugs targeting micro RNAs for treating various diseases.
Symbol: RGLS
Recent Price: $1.50
Industry: Biotechnology
CEO: Mr. Joseph P. Hagan M.B.A.
Sector: Healthcare
Employees: 30
Address: 4224 Campus Point Court, San Diego, CA 92121
Phone: 858 202 6300
Last updated: 2024-12-31
Scopus BioPharma Inc.
Duet Platform
Scopus Bio Pharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics for serious diseases with lead programs in immuno-oncology gene therapy.
Symbol: SCPS
Recent Price: $0.00
Industry: Biotechnology
CEO: Dr. Alan D. Horsager Ph.D.
Sector: Healthcare
Employees: 13
Address: 420 Lexington Avenue, New York, NY 10170
Phone: 212 479 2513
Last updated: 2024-12-31
Solid Biosciences Inc.
SGT-001
Solid Biosciences Inc. focuses on developing therapies for Duchenne muscular dystrophy, with lead product candidates like SGT-001 and SGT-003, and platform technologies like dual gene expression. The company is headquartered in Cambridge, Massachusetts, and collaborates with Ultragenyx Pharmaceutical Inc.
Vision/Values | Vision/Values | Vision/Values | About | Management | Directors | About | About | About | Culture | Benefits | About | Culture | Vision/Values | Contact | Contact | About | About
Symbol: SLDB
Recent Price: $4.07
Industry: Biotechnology
CEO: Mr. Alexander G. Cumbo
Sector: Healthcare
Employees: 88
Address: 141 Portland Street, Cambridge, MA 02139
Phone: 617 337 4680
Leadership
- Ian F. Smith, Chairman of the Board
- Bo Cumbo, President and CEO
- Martin Freed, M.D., F.A.C.P., Board Member
- Ilan Ganot, Co-Founder and Strategic Advisor to the CEO
- Clare Kahn, Ph.D., Board Member
- Georgia Keresty, Ph.D., M.PH., Board Member
- Sukumar Nagendran, M.D., President, Head of Research & Development, Taysha Gene Therapies
- Adam Stone, Chief Investment Officer of Perceptive Advisors
- Lynne Sullivan, Chief Financial Officer at Unity Biotechnology
Last updated: 2024-12-31
Soligenix, Inc.
SGX301 (Hy Bryte), SGX942, SGX203, SGX302
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases, operating in the Specialized Bio Therapeutics and Public Health Solutions segments.
About | Directors | About | About | About | About | About | About | Contact | About | About | About | About | About | Careers | Careers | About | About | About | About | About | About | About
Symbol: SNGX
Recent Price: $2.91
Industry: Biotechnology
CEO: Dr. Christopher J. Schaber Ph.D.
Sector: Healthcare
Employees: 13
Address: 29 Emmons Drive, Princeton, NJ 08540
Phone: 609 538 8200
Leadership
- Christopher J. Schaber, PhD, Chairman, President and Chief Executive Officer
- Gregg A. Lapointe, CPA, MBA, Board Director
- Diane L. Parks, MBA, Board Director
- Robert J. Rubin, MD, Board Director
- Jerome Zeldis, MD, PhD, Board Director
Last updated: 2024-12-31
2seventy bio, Inc.
idecabtagene vicleucel
2seventy bio, Inc. is a cell and gene therapy company focusing on cancer treatment research, development, and commercialization, with products including idecabtagene vicleucel and collaborations with Bristol-Myers Squibb.
Symbol: TSVT
Recent Price: $2.89
Industry: Biotechnology
CEO: Mr. William D. Baird III, M.B.A.
Sector: Healthcare
Employees: 274
Address: 60 Binney Street, Cambridge, MA 02142
Phone: 339 499 9300
Last updated: 2024-12-31
Abeona Therapeutics Inc.
EB-101
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa.
Symbol: ABEO
Recent Price: $5.61
Industry: Biotechnology
CEO: Dr. Vishwas Seshadri M.B.A., Ph.D.
Sector: Healthcare
Employees: 84
Address: 1330 Avenue of the Americas, New York, NY 10019
Phone: 646 813 4701
Last updated: 2024-12-31
Galecto, Inc.
GB2064
Galecto, Inc. is a clinical-stage biotechnology company focused on developing molecules for the treatment of fibrosis, cancer, inflammation, and related diseases. Their lead product candidate, GB2064, is in Phase IIa for myelofibrosis. The company also advances other candidates targeting severe fibrotic lung diseases and cancer.
Symbol: GLTO
Recent Price: $4.60
Industry: Biotechnology
CEO: Dr. Hans T. Schambye M.D., Ph.D.
Sector: Healthcare
Employees: 13
Address: 75 State Street, Boston, MA 02109
Phone: 457 070 5210
Last updated: 2024-12-31
Stoke Therapeutics, Inc.
STK-001, STK-002
Stoke Therapeutics, Inc. is an early-stage biopharmaceutical company focused on developing antisense oligonucleotide medicines to treat genetic diseases. Their lead product, STK-001, is aimed at treating Dravet syndrome, while STK-002 targets autosomal dominant optic atrophy.
Symbol: STOK
Recent Price: $10.80
Industry: Biotechnology
CEO: Dr. Edward M. Kaye M.D., Ph.D.
Sector: Healthcare
Employees: 110
Address: 45 Wiggins Avenue, Bedford, MA 01730
Phone: 781 430 8200
Leadership
- Edward M. Kaye, M.D., Chief Executive Officer & Director
- Jonathan Allan, J.D., General Counsel
- Isabel Aznarez, Ph.D., Senior Vice President, Discovery Research and Co-Founder
- Jason Hoitt, Chief Commercial Officer
- Dawn Kalmar, Chief Communications Officer
- Tommy Leggett, Chief Financial Officer
- Shamim Ruff, Chief Regulatory Officer
- Barry S. Ticho, M.D., Ph.D., FACC, Chief Medical Officer
- Joan Wood, Chief Human Resources Officer
- Adrian Krainer, Ph.D., Co-founder & Director
- Arthur Tzianabos, Ph.D., Chairman
- Jennifer Burstein, MBA, CPA, Director
- Seth L. Harrison, M.D., Director
- Arthur Levin, Ph.D., Director
- Garry E. Menzel, Ph.D., MBA, Director
- Ian F. Smith, Director
- Julie Anne Smith, Director
Last updated: 2024-12-31